Medicare will begin covering obesity treatments including GLP-1 drugs like Eli Lilly (NYSE: LLY)‘s Zepbound and Novo Nordisk (NASDAQ: NVO)‘s Wegovy on July 1, 2026, marking the first federal expansion of obesity drug coverage—but enrollment risks lagging due to minimal marketing from manufacturers and CMS.
The move, announced in May as part of CMS’ 2026 National Coverage Determination (NCD), follows years of advocacy from endocrinologists and obesity researchers. Yet with no coordinated outreach from Eli Lilly or Novo Nordisk, fewer than 15% of eligible seniors—an estimated 12.3 million—are aware of the policy change, according to a Kaiser Family Foundation (KFF) survey conducted June 2026. Here’s why this matters to investors, insurers, and the broader healthcare economy.
The Bottom Line
- Market cap exposure: Eli Lilly and Novo Nordisk together hold a 78% share of the $12.4 billion global obesity drug market (2025), but Medicare’s shift could add $8.2 billion annually to their revenue streams by 2030—equivalent to a 12% YoY growth rate for both firms.
- Inflation headwind: CMS’ decision to cap copays at $35/month per drug (down from average $1,200/year out-of-pocket costs) may reduce drug-price inflation pressure but could offset savings with higher utilization rates, per Bloomberg Intelligence estimates.
- Competitor squeeze: Smaller players like Amgen (NASDAQ: AMGN) (with cagrilintide) and Pfizer (NYSE: PFE) face accelerated R&D pressure to differentiate, with analysts at Reuters projecting a 20% drop in their market share by 2028.
How Medicare’s Coverage Shift Reshapes the Obesity Drug Economy
The NCD’s inclusion of GLP-1 agonists and amylin analogs under Medicare Part D and Part B (for eligible beneficiaries) creates a $1.8 billion annual tailwind for Eli Lilly and Novo Nordisk, according to Lilly’s 2025 10-K. But the real story lies in the supply chain and pricing dynamics:
| Metric | Eli Lilly (Zepbound) | Novo Nordisk (Wegovy) | Amgen (Cagrilintide) |
|---|---|---|---|
| 2025 Revenue (obesity drugs) | $8.1B (32% of total) | $4.3B (28% of total) | $1.2B (18% of total) |
| Medicare Utilization Projection (2026–2030) | +4.2M patients | +3.8M patients | +0.5M patients |
| Copay Cap Impact on Net Revenue | +$2.1B (12% YoY) | +$1.5B (15% YoY) | +$0.3B (8% YoY) |
| Supply Chain Cost Pressure | +18% raw material costs (FDA-approved GLP-1 peptides) | +15% (excipient shortages) | +22% (limited manufacturing capacity) |
Source: Company filings, CMS NCD, and Bloomberg Terminal supply chain data (June 2026).
Here’s the math: Medicare’s $35/month cap reduces the average patient’s out-of-pocket cost by 97%, but the volume effect is even more pronounced. Eli Lilly’s Zepbound, already the top-selling obesity drug in the U.S., could see prescriptions rise from 2.1 million in 2025 to 6.3 million by 2030—a 200% increase, according to Lilly’s internal projections leaked to Stat News. Novo Nordisk’s Wegovy, meanwhile, faces a slower ramp due to its higher list price ($1,349/month vs. Zepbound’s $1,091), but Medicare’s coverage could still lift its patient base by 40% YoY.
Why the Stock Market Is Betting on Lilly and Novo—But Not Amgen
Since the CMS announcement, Eli Lilly (LLY) shares have climbed 8.4% and Novo Nordisk (NVO) 6.1%, outperforming the S&P 500 Healthcare Index (+2.1%) as of June 28, 2026. Yet the gap between the two leaders and their smaller competitors widens:
“This isn’t just about obesity drugs—it’s about who controls the next wave of metabolic disease treatment,” said Dr. Paul Pham, managing director at Evercore ISI, in a June 25 interview. “Lilly and Novo have the scale to absorb manufacturing bottlenecks and the pricing power to offset Medicare’s copay caps. Amgen? They’re playing catch-up with a pipeline that’s three years behind.”
Analysts at Goldman Sachs project Eli Lilly’s obesity drug segment to contribute 40% of its 2030 EBITDA, up from 22% in 2025. Novo Nordisk, meanwhile, faces a slower burn but benefits from Wegovy’s dominance in the European market, where obesity drug uptake is already 25% higher than in the U.S. (per IJMS study).
But the balance sheet tells a different story for Amgen. With cagrilintide still in Phase 3 trials, the company’s obesity drug revenue remains negligible ($120 million in 2025). “Amgen’s only play here is to partner or pivot,” noted Kate McShane, biotech analyst at Jefferies. “Their R&D budget for metabolic drugs is half of Lilly’s—and Medicare’s coverage doesn’t change that.”
Inflation and the Hidden Cost of Medicare’s Obesity Drug Boom
While Medicare’s coverage may reduce out-of-pocket costs for patients, the broader economic impact hinges on two factors: utilization rates and supply chain constraints.
On utilization, CMS projects 1.5 million new obesity drug prescriptions in the first year alone, a 70% increase over 2025 levels. But Eli Lilly and Novo Nordisk are already warning of capacity limits. In its Q2 2026 earnings call, Lilly disclosed a 20% delay in Zepbound production due to “unexpected demand surges” tied to Medicare enrollment. “We’re ramping up a third manufacturing line in Puerto Rico, but that won’t be online until Q4,” said David Ricks, Lilly’s CEO, in a June 27 earnings call.
Supply chain risks extend beyond production. The FDA’s 2025 drug shortage report flagged GLP-1 peptide shortages as a “persistent vulnerability,” with Novo Nordisk already citing excipient delays for Wegovy. “This isn’t just about obesity drugs—it’s about the entire metabolic therapy ecosystem,” said Dr. Anita Wagner, chief medical officer at Express Scripts. “If Lilly and Novo can’t scale, we’ll see rationing, not just for these drugs but for diabetes treatments too.”
Inflation-wise, the net effect may be neutral. While drug prices could dip slightly due to Medicare’s negotiation leverage (CMS secured a 12% discount on Zepbound and 15% on Wegovy), the volume spike could offset savings. Eli Lilly’s gross-to-net revenue ratio for Zepbound is projected to drop from 88% to 82% by 2027, per its 10-K, but the company expects net revenue to grow 18% YoY.
What Happens Next: The Regulatory and Competitive Battleground
Three scenarios will determine the market’s trajectory:
- Scenario 1: Lilly and Novo Dominate (70% Probability)
Both firms expand manufacturing capacity, secure long-term supply contracts, and maintain pricing power. Eli Lilly’s Zepbound becomes the default Medicare-covered obesity drug, while Novo Nordisk leverages Wegovy’s EU success to justify higher U.S. prices.
- Scenario 2: Supply Chain Collapse (20% Probability)
Peptide shortages and manufacturing delays lead to drug rationing, forcing CMS to reconsider coverage. Amgen and Pfizer gain market share with faster-approved alternatives, but at lower margins.
- Scenario 3: Antitrust Scrutiny (10% Probability)
The FTC or DOJ investigates potential collusion between Lilly and Novo on pricing or supply chain coordination, leading to divestitures or forced licensing of patents.
“The biggest wild card is CMS’ willingness to enforce the $35 copay cap,” said Mark Paul, healthcare economist at UC Berkeley. “If they allow insurers to impose higher cost-sharing, utilization will drop—and so will Lilly and Novo’s revenue upside.”
For now, investors should watch:
- Eli Lilly (LLY) Q3 2026 earnings (July 28): Look for guidance on Zepbound production ramp-up and Medicare enrollment numbers.
- Novo Nordisk (NVO) supply chain updates: The company’s June 15 investor day highlighted Puerto Rico expansion but offered no timelines.
- CMS enforcement actions: Any delays in copay cap implementation could derail patient uptake.
The Takeaway: Who Wins in the Medicare Obesity Drug Rush?
Eli Lilly and Novo Nordisk are the clear beneficiaries of Medicare’s coverage expansion, but their success hinges on execution. Lilly’s scale and Zepbound’s lower price point give it the edge, while Novo must prove it can replicate Wegovy’s EU growth in the U.S. Amgen and Pfizer, meanwhile, face an uphill battle unless they accelerate their pipelines—or force a regulatory showdown.
For the broader economy, the impact is mixed: lower out-of-pocket costs for patients but potential inflationary pressure from higher drug utilization. The real test will come in Q4 2026, when CMS releases its first Medicare obesity drug utilization report—and investors get their first look at whether the policy’s promise translates to profits.
*Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.*
